Mimedx (MDXG) Non-Current Assets (2010 - 2026)
Mimedx (MDXG) posted Non-Current Assets of $75.6 million for Q2 2026, up 10.66% sequentially from $68.4 million in Q1 2026, and up 7.69% YoY from $70.2 million in Q2 2025.
Mimedx (MDXG) Non-Current Assets (2010 - 2026) Analysis & Trends
Mimedx has reported Non-Current Assets for 17 years, with the latest figure at $75.6 million in Q2 2026.
- Quarterly Non-Current Assets rose 7.69% year-over-year to $75.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $274.1 million (down 3.61% YoY) and the FY2025 annual result came in at $65.2 million, down 9.51% from the prior year.
- Non-Current Assets climbed to $75.6 million in Q2 2026 per MDXG's latest filing, from $68.4 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $82.8 million in Q1 2024 and troughed at $34.5 million in Q3 2023.
- A 5-year average of $58.2 million and a median of $66.8 million in 2025 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2024 and 2025: Non-Current Assets soared 127.19% in 2024, then slipped 15.12% in 2025.
- Over 5 years, Non-Current Assets stood at $37.2 million in 2022, then jumped by 100.86% to $74.8 million in 2023, then dropped by 3.69% to $72.0 million in 2024, then retreated by 9.51% to $65.2 million in 2025, then rose by 16.03% to $75.6 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $75.6 million, $68.4 million, and $65.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Mimedx | 622.24 Mn | 486.40 Mn | 44.38 Mn | 75.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 75.63 Mn |
| Mar 31, 2026 | 68.35 Mn |
| Dec 31, 2025 | 65.18 Mn |
| Sep 30, 2025 | 64.89 Mn |
| Jun 30, 2025 | 70.23 Mn |
| Mar 31, 2025 | 70.31 Mn |
| Dec 31, 2024 | 72.03 Mn |
| Sep 30, 2024 | 71.75 Mn |
| Jun 30, 2024 | 76.17 Mn |
| Mar 31, 2024 | 82.83 Mn |
| Dec 31, 2023 | 74.79 Mn |
| Sep 30, 2023 | 34.52 Mn |
| Jun 30, 2023 | 35.16 Mn |
| Mar 31, 2023 | 36.46 Mn |
| Dec 31, 2022 | 37.23 Mn |
| Sep 30, 2022 | 36.76 Mn |
| Jun 30, 2022 | 37.66 Mn |
| Mar 31, 2022 | 38.54 Mn |
| Dec 31, 2021 | 39.41 Mn |
| Sep 30, 2021 | 38.62 Mn |